Literature DB >> 20104281

Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.

Gianna Franca Rivolta1, Caterina Di Perna, Massimo Franchini, Federica Riccardi, Luigi Ippolito, Maria Lombardi, Annarita Tagliaferri.   

Abstract

Entities:  

Keywords:  FVIII/VWF concentrate; ITI; haemophilia A; inhibitor

Mesh：

Substances：

Year:  2010        PMID： 20104281      PMCID： PMC2809514          DOI： 10.2450/2009.0078-09

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  16 in total

Review 1.  Immune tolerance induction: recombinant vs. human-derived product.

Authors:  E Berntorp
Journal:  Haemophilia       Date:  2001-01       Impact factor: 4.287

2.  Venous thromboembolism in von Willebrand disease.

Authors:  P M Mannucci
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

3.  Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors.

Authors:  Frédérique Orsini; Chantal Rotschild; Philippe Beurrier; Albert Faradji; Jenny Goudemand; Benoît Polack
Journal:  Haematologica       Date:  2005-09       Impact factor: 9.941

Review 4.  Role of von Willebrand factor in immune tolerance induction.

Authors:  Carmen Escuriola Ettingshausen; Wolfhart Kreuz
Journal:  Blood Coagul Fibrinolysis       Date:  2005-04       Impact factor: 1.276

5.  International workshop on immune tolerance induction: consensus recommendations.

Authors:  D M DiMichele; W K Hoots; S W Pipe; G E Rivard; E Santagostino
Journal:  Haemophilia       Date:  2007-07       Impact factor: 4.287

Review 6.  The role of VWF for the success of immune tolerance induction.

Authors:  Wolfhart Kreuz
Journal:  Thromb Res       Date:  2008       Impact factor: 3.944

7.  Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.

Authors:  M Shima; H Nakai; D Scandella; I Tanaka; Y Sawamoto; S Kamisue; S Morichika; T Murakami; A Yoshioka
Journal:  Br J Haematol       Date:  1995-11       Impact factor: 6.998

Review 8.  The epidemiology of inhibitors in haemophilia A: a systematic review.

Authors:  J Wight; S Paisley
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287

Review 9.  The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Authors:  Günter Auerswald; Torsten Spranger; Hans-Hermann Brackmann
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

Review 10.  Epidemiology of inhibitors and current treatment strategies.

Authors:  Wolfhart Kreuz; Carmen Escuriola Ettingshausen; Günter Auerswald; Inmaculada Martinez Saguer; Sabine Becker; Markus Funk; Christine Heller; Dieter Klarmann; Thomas Klingebiel
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.